Fischer Imaging of Denver received a warning letter from the Food and Drug Administration last month for deficiencies in its manufacturing documentation processes. The notification is the second time in two years that Fischer has received a warning
Fischer Imaging of Denver received a warning letter from the Food and Drug Administration last month for deficiencies in its manufacturing documentation processes. The notification is the second time in two years that Fischer has received a warning letter from the agency (SCAN 5/10/95).
The warning letter follows a six-week FDA inspection that took place late last year as part of a routine biennial audit of Fischer's manufacturing facility, according to Sammy Emrich, director of regulatory affairs at Fischer. In the letter, the FDA expressed concern with manufacturing documentation, as well as the methods Fischer uses to determine trends in its manufacturing process.
Fischer is responding to the letter by improving its documentation processes, examining better system reporting, and establishing product improvement teams, Emrich said. The FDA did not find fault with Fischer's products or the manufacturing process itself, she said.
In the warning letter Fischer received two years ago, the FDA cited Fischer for improper follow-up on repairs, inadequate analysis of product failures, and assigning to a single employee both quality assurance and manufacturing functions. Fischer complied with FDA concerns in that case, and the most recent letter commented on some of the improvements Fischer made in response to the first letter.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.